Thromboelastography identifies preoperative hypercoagulability in surgical patients with high stroke risk scores: A cross-sectional study Authors: Haixia Tang, Wei Yu, Ningmei Liang, Bangsheng Hu Published: 2026 ABSTRACT AimThis study aimed to evaluate the value of thromboelastography as a complementary tool for identifying hypercoagulability in surgical patients at high risk for stroke by comparing its parameters with those of conventional coagulation tests and benchmarking them against healthy controls.MethodsTwo hundred and twenty patients at high risk for stroke and 40 healthy controls were recruited from a large central hospital in China between December 2019 and March 2022. The thromboelastography 5000 technology was used to acquire the thromboelastography parameters.ResultsPatients at high risk for stroke exhibited a more hypercoagulable state than healthy participants. Among patients at high risk for stroke, the high D-dimer group showed a significantly stronger hypercoagulable profile than the normal D-dimer group. The correlation between thromboelastography parameters and conventional coagulation tests was consistent with a hypercoagulable state in patients at high risk for stroke.ConclusionsThromboelastography may be useful for identifying a preoperative hypercoagulable state in this patient group, but further research is needed to determine whether such detection translates into improved clinical decision-making or outcomes. Introduction Stroke is a well-known cerebrovascular disease that can lead to clinical symptoms of neurological dysfunction. 1 Stroke may cause severe long-term disability. A lack of appropriate treatment, especially in patients without reperfusion, contributes to subsequent disability. 2 According to the guidelines from the Society for Critical Care, perioperative stroke is defined as a brain infarction occurring during surgery or within 1 month after surgery. 3 Identification of perioperative stroke can be challenging during the surgical period, and patients experiencing perioperative stroke receive treatment less frequently than patients with community-onset stroke. The probability of perioperative ischemic stroke is approximately 0.1%–1.9%. 4 The main cause of most strokes is thrombosis, and corresponding susceptibility factors include age, stroke history, atrial fibrillation, and metabolic disorders, which can be combined to predict stroke risk. 5 In addition, for patients who received anticoagulation or antiplatelet therapy before surgery, the hypercoagulable state caused by the withdrawal of antithrombotic drugs before surgery also increases the risk of thromboembolic events in the perioperative period. 6 Therefore, preventing perioperative stroke is an urgent problem for clinicians to solve. Thromboelastography (TEG), first invented in 1948, is an effective hemostatic evaluation method that is widely applied in cardiac surgery, obstetrics, and orthopedic surgery.7–10 During the global coronavirus disease 2019 (COVID-19) pandemic, TEG was used to recognize and evaluate the hypercoagulable state in patients with COVID-19. 11 Conventional coagulation tests (CCTs) assess only isolated components of the coagulation cascade and do not reflect the overall hemostatic process. In contrast, TEG may provide real-time, global visualization of coagulation, enabling dynamic assessment of hemostatic function and complementing the information provided by CCTs.12–14 This study aimed to evaluate the value of TEG as a complementary tool for identifying hypercoagulability in surgical patients at high risk for stroke, by comparing its parameters with those of CCTs and benchmarking them against healthy controls. Methods Patients and study design A total of 220 patients at high risk for stroke and 40 healthy controls were recruited from a large central hospital in China between December 2019 and March 2022. The inclusion criteria for patients at high risk for stroke were as follows: (a) Essen Stroke Risk Score ≥ 3; (b) patients who underwent noncardiac and nonbrain surgery; and (c) age >18 years. The exclusion criteria were as follows: (a) hematological disease, (b) severe liver or kidney disease, and (c) refusal to participate in the postoperative follow-up. This study was approved by the Ethics Committee of The First Affiliated Hospital of Wannan Medical University (approval number: ChiECRCT20190238, date: 10 November 2019). The study was conducted in accordance with the Declaration of Helsinki (1975), as revised in 2024. Each participant signed a written informed consent form after being fully informed about the study procedures. All patient data were anonymized to protect confidentiality, and no personal identifiers are present in the manuscript. The trial is recorded on the Chinese Clinical Trial Registry website (ChiCTR1900027784). The reporting of this cross-sectional study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. 15 Preoperative CCTs and TEG The preoperative CCTs included activated partial thromboplastin time (APTT), platelet count (PLT), and other laboratory parameters (prothrombin time (PT), international standardized ratio (INR), fibrinogen (FIB), and D-dimer (DD)). In addition, TEG tests were performed simultaneously before surgery, and the TEG 5000 technology was used to acquire the TEG parameters. TEG was performed using the TEG® 5000 Hemostasis Analyzer (Haemonetics Corporation, Braintree, MA, USA) with kaolin-activated citrated whole blood. Blood samples were collected in 3.2% sodium citrate tubes and analyzed within 2 h of venepuncture. Recalcification was performed with 0.2 M CaCl2 according to the manufacturer’s protocol. The TEG parameters included K, R, alpha angle, and MA. The coagulation index (CI) is a calculated composite parameter derived from R, K, alpha angle, and MA, where CI >+3 indicates hypercoagulability, CI between −3 and +3 is normal, and CI <−3 indicates hypocoagulability. CI values were automatically generated by the TEG® 5000 software. Preoperative use of antiplatelet agents (aspirin, clopidogrel) and anticoagulants (DOACs, warfarin) was documented. Standardized washout periods (5–7 days for antiplatelets; 24–48 h for DOACs depending on renal function; 5 days for warfarin) were applied per hospital protocol, and the exact time of the last dose was recorded prior to blood sampling. Statistical analysis Based on a pilot study with 10 patients per group, assuming an effect size of 0.6 for the primary parameter (MA), with α = 0.05 and power = 0.80, a minimum of 36 subjects per group was required. We recruited 40 controls to allow for potential exclusions and 220 patients to ensure sufficient power for subgroup analyses. The Shapiro–Wilk test was used to check for normality in the statistical analysis, which was conducted using IBM SPSS Statistics for Windows version 26 (IBM Corp., Armonk, NY, USA). The mean ± SD was used to express measurement data that followed a normal distribution. Interquartile ranges and medians were used to describe other measurement data. For normally distributed data, independent samples t-tests were used for comparisons between two groups, and one-way analysis of variance was employed for comparisons involving more than two groups. For non-normally distributed data, the Mann–Whitney U test was applied for two-group comparisons. Depending on the sample size, the chi-square or Fisher’s exact test was used to analyze count data. Statistical significance was set at p < 0.05. Results Basic characteristics of patients and healthy controls A total of 220 patients at high risk for stroke were enrolled, with a mean age of 75.43 ± 6.48 years, including 114 males and 106 females. There were 40 healthy controls, with an average age of 44.23 ± 10.73 years, including 20 males and 20 females. Significant differences were noted in the American Society of Anesthesiologists score (ASA), age, hypertension, diabetes, smoking, coronary artery disease (CAD), ischemic stroke, and transient ischemic attack (TIA) (p < 0.05) (Table 1). There were no significant differences in sex or body mass index (BMI). During the 90-day postoperative follow-up, no clinical stroke or thromboembolic events were recorded in the high-risk patient cohort. Table 1.Basic characteristics of included patients.VariableHG (n = 220)CG (n = 40)p valueASA score 2 >256 16432 8<0.05Male/female114/10620/200.971Age (years)75.43 ± 6.4844.23 ± 10.73<0.05BMI (kg/m2)22.54 ± 3.5621.45 ± 1.900.313Hypertension (%)168 (76.4%)5 (12.5%)<0.05Diabetes (%)82 (37.3%)2 (5.0%)<0.05Smoking (%)32 (14.5%)3 (7.5%)<0.05CAD (%)45 (20.5%)1 (2.5%)<0.05Ischemic stroke/TIA (%)78 (35.5%)3 (7.5%)<0.05ASA: American Society of Anesthesiologist Physical Status Classification; BMI: body mass index; CAD: coronary artery disease; CG: control group; HG: high-risk stroke group; TIA: transient ischemic attack. Basic characteristics of included patients. ASA: American Society of Anesthesiologist Physical Status Classification; BMI: body mass index; CAD: coronary artery disease; CG: control group; HG: high-risk stroke group; TIA: transient ischemic attack. Comparison of coagulation parameters between the high-risk and control groups The high-risk group had significantly higher values of prothrombin time, FIB, international normalized ratio, and DD compared with the control group (p < 0.05; Table 2). In contrast, no significant differences were observed in APTT or platelet count between the two groups. Regarding thromboelastography parameters, the high-risk group exhibited a hypercoagulable pattern, characterized by shortened R and K values and increased alpha angle and maximum amplitude (MA), all of which were statistically significant (p < 0.05; Table 2). Table 2.Comparison of CCTs and TEG parameters among included patients.ParametersHG (n = 220)CG (n = 40)p valuePT (s)12.20 (11.50–12.90)11.5 (10.8–12.1)<0.05APTT (s)27.85 (26.20–30.30)27.40 (26.20–28.50)0.242DD (μg/mL)0.70 (0.34–2.07)0.21 (0.19–0.37)<0.05FIB (g/L)3.32 (2.72–4.37)2.63 (2.31–3.05)<0.05INR1.03 (0.98–1.10)0.99 (0.93–1.02)<0.05PLT (109/L)168.00 (137.00–206.00)170.00 (135.25–244.25)0.572R (min)5.90 (4.90–7.00)7.20 (6.40–8.00)<0.05K (min)1.3 (1.20–1.70)1.9 (1.7–2.0)<0.05Alpha angle (°)69.80 (64.10–73.40)63.3 (62.5–65.10)<0.05MA (mm)66.60 (62.75–73.40)60.90 (56.40–65.20)<0.05APTT: activated partial thromboplastin time; CCTs: conventional coagulation tests; CG: control group; DD: D-dimer; FIB: fibrinogen; HG: high risk group of stroke; INR: international standardized ratio; PLT: platelet count; PT: prothrombin time; TEG: thromboelastography. Comparison of CCTs and TEG parameters among included patients. APTT: activated partial thromboplastin time; CCTs: conventional coagulation tests; CG: control group; DD: D-dimer; FIB: fibrinogen; HG: high risk group of stroke; INR: international standardized ratio; PLT: platelet count; PT: prothrombin time; TEG: thromboelastography. Comparison of TEG levels between the high DD and normal DD groups Among 220 patients at high risk for stroke, 121 patients were in the high DD group (DD ≥ 0.5 μg/mL), and 99 patients were in the normal DD group (DD < 0.5 μg/mL). Patients with elevated DD (≥0.5 μg/mL) exhibited a significantly more pronounced hypercoagulable state on TEG compared with those with normal DD levels, as reflected by shorter R and K values, increased alpha angle and MA, and higher CI (all p < 0.05; Table 3). Table 3.Comparison of TEG parameters between high DD group and normal DD group.TEG parametersHigh DD group (n = 121)Normal DD group (n = 99)p valueR (min)5.70 (4.78–6.68)6.00 (5.00–7.00)0.312K (min)1.25 (1.08–1.50)1.50 (1.20–1.80)<0.05Alpha angle (°)70.70 (65.05–74.53)68.20 (62.75–72.25)<0.05MA (mm)68.15 (63.75–73.43)65.80 (60.90–69.35)<0.05DD: D-dimer; TEG: thromboelastography. Comparison of TEG parameters between high DD group and normal DD group. DD: D-dimer; TEG: thromboelastography. Association between TEG parameters and CCTs Spearman's rank correlation coefficient was used to determine the association between TEG parameters and CCTs. The R values were positively correlated with APTT (p < 0.05) (Table 4). The alpha angle, MA, and CI were positively correlated with FIB and PLT levels (p < 0.05) (Table 4). In addition, K values were negatively correlated with PLT, and CI values were inversely associated with APTT (p < 0.05) (Table 4). Table 4.Spearman's coefficient correlation (r) was performed to evaluate the association of TEG parameters and CCTs. PT (s)APTT (s)DD (μg/mL)FIB (g/L)INRPLT (109/L)R (min)0.0760.202*−0.096−0.017−0.029−0.015K (min)0.0560.094−0.115−0.2310.011−0.198*Alpha angle (°)−0.24−0.110.0730.212*0.0040.210*MA (mm)0.1100.0560.1150.506*−0.0420.316*CI−0.007−0.137*0.1320.314*0.0020.214**p < 0.05.APTT: activated partial thromboplastin time; CCTs: conventional coagulation tests; DD: D-dimer; FIB: fibrinogen; INR: international standardized ratio; PLT: platelet count; PT: prothrombin time; TEG: thromboelastography. Spearman's coefficient correlation (r) was performed to evaluate the association of TEG parameters and CCTs. *p < 0.05. APTT: activated partial thromboplastin time; CCTs: conventional coagulation tests; DD: D-dimer; FIB: fibrinogen; INR: international standardized ratio; PLT: platelet count; PT: prothrombin time; TEG: thromboelastography. Discussion Our findings demonstrate that surgical patients with a high stroke risk score showed a hypercoagulable profile on TEG compared with healthy controls, characterized by shortened R and K values and increased alpha angle and MA values. These observations suggest that TEG may capture a global hypercoagulable state in this population, although the marked age and comorbidity differences between groups prevent these differences from being attributed solely to stroke risk. The observed hypercoagulability may reflect age-related increases in platelet aggregation and fibrinogen levels, as previously reported, 16 although other factors—such as inflammation or metabolic disturbances—could also contribute. Within the high-risk group, patients with elevated DD levels (≥0.5 μg/mL) exhibited a significantly more pronounced hypercoagulable profile on TEG than those with normal DD levels, consistent with the TEG findings of shortened R/K and increased alpha angle/MA/CI. This association suggests that elevated DD may reflect ongoing thrombin generation and fibrin turnover in this population, providing a mechanistic link between the hypercoagulable state detected by TEG and the increased thrombotic risk. Previous studies have shown that DD levels can predict short-term adverse outcomes in acute ischemic stroke, further supporting the clinical relevance of this observation. 17 Taken together, these findings suggest that an altered coagulation profile may play a role in the pathophysiology of stroke, although the cross-sectional design does not permit causal inferences. The correlation patterns between TEG parameters and CCTs further support the presence of hypercoagulability in this high-risk population. Previous studies have shown that the K, R, and MA values are significantly correlated with traditional coagulation parameters.14,18 Mechanistically, the K and alpha angle reflect the rate of clot formation and are closely linked to fibrin function, whereas MA represents maximum clot strength and is primarily determined by platelet function. 12 In our study, three parameter pairs (R-APTT, K-APTT, and alpha angle-FIB) consistently identified hypercoagulability, reinforcing the complementary value of TEG to CCTs. Recent studies have reported that TEG parameters are sensitive indicators of hypercoagulability and may assist in guiding therapy for acute cerebral infarction, 19 and that enhanced platelet activity assessed by TEG reflects enhanced platelet reactivity in patients with ischemic stroke. 20 These observations suggest that TEG could be a promising tool for evaluating perioperative coagulation status in patients at high risk for stroke. However, given that no stroke events occurred in our cohort, we cannot conclude that TEG predicts perioperative stroke; this question warrants prospective investigation. This study has several limitations. First, the marked age difference between the high-risk patients and the younger healthy controls is a significant confounder. Second, the absence of stroke events precludes any conclusion regarding the predictive value of TEG for perioperative stroke. Third, the lack of routine postoperative neuroimaging means asymptomatic infarcts could have been missed. Fourth, the single-center design and modest sample size may limit generalizability. Fifth, variations in preoperative antithrombotic management were not controlled for, potentially affecting coagulation profiles. Furthermore, covert stroke is increasingly recognized in the perioperative period, particularly in elderly patients, with reported incidences of up to 7%.21,22 Although no stroke events were documented during the 90-day follow-up, asymptomatic infarcts could not be ruled out in the absence of routine postoperative imaging. The lack of multivariable adjustment for confounders is a limitation, and our findings should be interpreted as exploratory and hypothesis-generating, requiring confirmation in larger prospective studies with appropriate statistical modeling. Conclusions Therefore, TEG may be useful for identifying a preoperative hypercoagulable state in this patient group, but further research is needed to determine whether such detection can translate into improved clinical decision-making or outcomes.